cal journal? Is it not a conflict-of-interest (COI) for clinicians reading this journal to be subjected to slick advertisements? Or are well-educated healthcare providers above it all; better able, perhaps than parents, to ignore the enticements and persuasions found in advertising?
The short answer is: Yes, it does create a professional COI if one's clinical behaviors are influenced by commercial entities. As healthcare providers (HCPs), our fiduciary obligation is owed to the folks we care for: To provide good healthcare, in the best interests of the patient/client (Wood, 2009) . Companies (whether publicly-or privatelyowned) owe a fiduciary obligation to the owners: To operate in the best interests of the commercial entity, by making profits (Nolo, n.d.) . Imagine HCPs in one circle (with a motive to care for patients/clients), and commercial interests in another circle (with a motive to make profits for the company). Now imagine the two circles moving toward one another, and starting to overlap, in a Venn Diagram (or a partial eclipse). This creates a zone of tension between the competing interests, where the duty of providing good, evidence-based healthcare overlaps (is eclipsed by?) the duty to make money. Ethicists call the overlap zone a professional conflict-of-interest ("We both care about the same thing here, but different motives fuel our decisionmaking and action"). The corporate interests are likely to characterize the overlap zone as an opportunity for collaboration ("We both care about the same thing here; we have a lot in common and should share in decision-making and action!"). Collaborative public-private partnerships are catching on in public health circles (World Health Organization [WHO], n.d.), much to the dismay of advocates concerned about COI (Moynihan, Macdonald, Heneghan, Bero, & Godlee, 2019) .
Like it or not, we HCPs are constantly being unduly persuaded by messaging and advertisements from commercial vendors. We are influenced all day, every day, in both our personal and professional lives, by powerfully persuasive marketing techniques, designed to build brand loyalty. The advertisements and marketing tactics do not have to be false or misleading. Insidiously, we do not even realize the persuasion is happening, to the point where we overtly reject any suggestion that we are (or ever could be) influenced (Chugh, Bazerman, & Banaji, 2005) , or use tortured reasoning to justify acceptable conflicts (McCoy, 2017) , or simply bristle when called out on these inherent and overt COIs (Goldberg, 2014 (Goldberg, , 2015 Fineberg, 2017) . And while we bask in our hubris that we could never be "played" by undue influence, the corporations will be the very first ones to agree with us, as they laugh all the way to the bank.
This editorial describes, generally, how HCPs are subjected to marketing and persuasion techniques (including advertisements in journals) that are designed to influence clinical care. It suggests means to counteract these tactics, to reduce inappropriate influence when we interact with families.
journal of research articles. All publications-whether mass media intended for the public-at-large, or peer-reviewed journals intended for niche audiences of HCP specialists-have costs associated with staffing, editing, and publishing printed works. Large professional associations with tens of thousands of members have budgets that can draw upon large reservoirs of membership dues to publish a journal. Some smaller organizations, like the International Lactation Consultant Association (ILCA), use a combination of on-line and paper printing to attract as many readers as possible while containing costs. Most publications rely on advertisements-with fees paid by commercial interests-to provide income to cover production costs. The rub is that advertisers are looking to attract the eye of potential customers, and for the readers of JHL, this means advertisements from producers of goods and services intended to be used in lactation care and support. That is why we do not see advertisements for heart disease or arthritis medications in JHL, and advertisements for infant probiotics or nursing pillows do not show up in Sage's American Journal of Sports Medicine.
If JHL were to be published with no advertisements at all-removing all COI tensions-all costs would have to be covered by the ILCA budget for JHL. That would require a prohibitive increase in member dues for the 5-6,000 folks who are members of ILCA in any given year. Doubling or tripling dues would no doubt turn away new and returning members, and that would spell financial doom for both JHL and ILCA. Not a pretty picture. Thus, some sort of editorial balance must be struck, and journals struggle with just how to do that.
Marketing to HCPs by pharmaceutical and medical device (e.g., breast pump) manufacturers has been long-studied for the negative impact it has on clinical and prescribing behaviors (Lo & Field, 2009; Keller, Marczewski, & Pavlović, 2016) . Increasingly, professional associations and healthcare institutions are seeking (at best) a severing of ties between HCPs, researchers, and commercial interests, or (at the very least) full disclosure of any financial entanglements (International Code Documentation Centre, 2019; Grundy, Habibi, Schnier, Mayes, & Lipworth, 2018) . And yet, full disclosure does not erase the COI, nor does it eradicate the influence of the disclosed financial entanglement. It merely discloses it, allowing one to "come clean to play dirty." Indeed, Goldberg (2018, p. 1) persuasively argues that full sequestration ("defined as the elimination of relationships between commercial industries and health professionals in all cases where it is remotely feasible") is the only bioethical means to remedy COIs, as disclosure is "at best ineffective" (2018, p. 1).
An additional layer for lactation care givers is consideration for products falling under the scope of the International Code of Marketing of Breast-Milk Substitutes (IC). JHL, following the lead of its parent organization ILCA, does not accept any advertising dollars from companies that are not meeting their obligations under the IC (Sage Publishing, 2019). In recent years, under the current editorial team, JHL went one step further, and now also refuses any article submissions by authors who have been funded by such companies (Sage Publishing, 2019, June 17). This meets a high bar set by policies from the fields of public health, lactation support, healthcare, ethics, and ethical publishing that eschew any overlap of clinical care, education, and research with commercial-source funding-precisely because of overt and inherent COIs (American Public Health Association, 2007; WHO, 2016; Victora et al., 2016a Victora et al., , 2016b Lo & Field, 2009 ; Council of Medical Specialty Societies, 2015; Committee on Publication Ethics, 2019).
Lactation support professionals are keenly aware of their need to respect the IC. Professions advocating for breast/ chestfeeding, lactation support, and human milk use as a public health imperative, have been vocal about their support for the IC, since its initial adoption in 1981 and continuing into the 21 st century with its bi-annual review and updates at the World Health Assembly (WHA). The IC is a model policy: A call to action by governments to enact legislation, as the law of their land, to restrict predatory marketing to vulnerable populations. It articulates proscriptions against health workers taking (or being offered) any financial inducements from companies that produce and market the products falling under the scope of the IC (infant formula, bottles, teats, and early weaning foods/drinks intended to displace breastfeeding). Thus, IC analysis for health workers is really nothing more than a subset of COI analysis (International Baby Food Action Network & International Code Documentation Centre, 2018).
In sum: health workers providing lactation support and clinical care must be savvy about the potential for influence by marketers of pharmaceutical products, medical devices, and the four product-types falling under the scope of International Code.
Ethical Duty to Avoid Conflicts-of-Interest
For HCPs generally, and International Board Certified Lactation Consultants (IBCLCs) in particular, ethical professional codes of conduct recognize and prohibit conflicts-ofinterest. The International Board of Lactation Consultant Examiners (IBLCE) administers the Code of Professional Conduct for IBCLCs (IBLCE CPC), a mandatory practiceguiding document enforceable by an ethics and disciplinary process at IBLCE. Principle 5 of the IBLCE CPC states, "Exercise independent judgment and avoid conflicts of interest," and further requires at 5.1, "Disclose any actual or apparent conflict of interest, including a financial interest in relevant goods or services, or in organizations which provide relevant goods or services," and at 5.2, "Ensure that commercial considerations do not influence professional judgment" (IBLCE, 2015, p. 3). The Scope of Practice for International Board Certified Lactation Consultant® (IBCLC®) Certificants (IBLCE SOP), another mandatory practice-guiding document also administered by IBLCE, states at VI.1. that "IBCLC certificants have the duty to act with reasonable diligence by [p] roviding information that is evidence-based and free of conflict of interest" (IBLCE SOP, 2018, p. 2). This duty is explained further in the Clinical Competencies for the Practice of International Board Certified Lactation Consultants® (IBCLCs®; IBLCE CC) at VI.1.: "The IBCLC has the duty to act with reasonable diligence and will [a]ssist clients and families with decisions regarding feeding their child(ren) by providing evidence-based information that is free of any conflicts of interest" (IBLCE CC, 2018, p. 5).
In sum: IBCLCs (like other HCPs) are required by the ethical mandates of their profession to be free of the COIs generated by commercial entity marketing of pharmaceuticals, medical devices (e.g., breast pumps), and International-Code-covered products.
Influence and Persuasion Versus Conflict-of-Interest
What does any of this have to do with advertisements in peerreviewed journals? As it turns out: Just about everything.
Commercial interests would not spend billions of dollars, annually, in marketing to health care providers, unless they got a return on that investment (Schwartz & Woloshin, 2019) . The psychology of persuasion (and methods of influence) are well-known to marketers, advertisers, and those who study the overt and inherent ways our brains access information (consciously, and subconsciously), separate wheat-fromchaff, and come to decisions. Robert Cialdini's (2007) bestseller Influence: The Psychology of Persuasion lists the "weapons of influence" as follows:
1. Reciprocity (receiving even token gifts instills a sense that one must now return the favor) 2. Commitment and consistency (we want to be and appear to be consistent with what we have already done) 3. Social proof (we assume an action is correct if others are doing it) 4. Liking (building on reciprocity, commitment, and social proof, we tend to take actions for "likable" people and reasons) 5. Authority (built on "directed deference," a deepseated sense of duty to authority, whom we expect to be leaders and experts) 6. Scarcity (opportunities are seen as more valuable when their availability is limited).
Other authors have expanded upon the theme, demonstrating how the forces working on individual decision-making can be combined strategically and collectively by corporate interests to shape long-term public health initiatives inuring to corporate (rather than public health) benefit.
These "commercial determinants of health"-all quite legal, transparently conducted, and openly lauded-impact (and disregard) public morbidity and mortality, with an ultimate goal of enhancing the company's bottom line. Large corporate conglomerates wield tremendous power: Their markets are global in scope, enhanced by the internationalization of trade and investment, perpetually driving demand up. Corporate influence is exerted through four channels:
1. Marketing (to enhance brand loyalty and increase desirability/acceptability of unhealthy commodities) 2. Lobbying (to impede or diminish regulatory, legal, and policy barriers) 3. Corporate social responsibility strategies (to deflect inquiry and whitewash tarnished reputations), and 4. Extensive supply chains (that amplify company influence around the globe).
The intention is to create a universe of influence on individuals, communities, and the environment -with negative impacts (like poor health outcomes) seen as irrelevant to the greater objective of increasing market share and profit (Freudenberg, 2014; Kickbusch, Allen, & Franz, 2016) . While all of this may seem overly alarmist and outlandish, examples abound. The American Academy of Pediatrics has had long-standing and overt financial relationships with infant formula manufacturers, much to the consternation of its own Section on Breastfeeding (Sharfstein, 2017) . A leading formula manufacturer and IC-flouter hosted a three-day conference bringing in esteemed thought leaders, authors, and researchers in breastfeeding/lactation (Nestle Nutrition Institute, 2017). A pump manufacturer commencing a "certification" program for IBCLCs managed to demonstrate-in a one-page, 10-paragraph, public outreach document widely disseminated on social media-47 uses of subliminal persuasion techniques designed to trigger IBCLC buy-in (14 uses of brand name [triggering recognition and loyalty], nine uses of IBCLC [an esteemed authority], eight gift/freebie offers [reciprocity] , four examples of others in the program [social proof], and 12 appeals to likeability [both of purpose, and of early adopters]; Spectra Baby USA, 2017).
Those Advertisements for Even Non-COI Products Still Matter
All of the foregoing establishes that advertisements intended for a healthcare provider audience-even when the product is not on our radar (as an overt COI) as a pharmaceutical, medical device, or IC-covered product-are still intended to build brand loyalties that obscure how we dispassionately provide evidence-based care to our patients and clients. Brand recognition and loyalties "harmlessly" built for a pillow, herb, or IC-respective pump manufacturer will transfer should corporate mergers expand the product line. Educational programs sponsored by infant formula companies, to discuss matters wholly unrelated to lactation (e.g., wound healing), bathe the learner with logos, colors, and tag-lines, all to cement brand loyalty (Abbott Nutrition Health Institute, 2019) . As HCPs change job responsibilities, now perhaps moving into parent-child care, they bring their subconscious loyalties with them. As we observe respected mentors engage in these activities, we are persuaded that this "must be OK" under our ethical codes. 
Suggestions to Address Inevitable Influence on Clinical Behaviors

Summary
Healthcare providers are subjected to influence, persuasion, and marketing by commercial interests that have billions to spend to build brand recognition and perpetual market share. Effective techniques work on subconscious decision-making centers in the brain, and are designed to obfuscate dispassionate analysis and displace it with emotion-based loyalties. As respected members of the public-and medical-health community, HCPs resist the notion that they can be influenced against their primary duty of care to the patient/client. It is nearly impossible to eradicate the influence. Therefore, recognizing that these influences exist is the first step to diminishing their impact. Refusing any-and-all financial entanglements with commercial interests (full sequestration) considerably reduces conflicts-of-interest. Compelling (and complying with) academic, institutional, and journal requirements to fully disclose all financial entanglements permits colleagues to better assess articles, research, and teaching sessions.
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